Skip to main
PGEN
PGEN logo

Precigen (PGEN) Stock Forecast & Price Target

Precigen (PGEN) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Precigen Inc has demonstrated a strong potential for growth, particularly with the anticipated approval of PRGN-2012, which is positioned as the leading therapy for recurrent respiratory papillomatosis (RRP). The company has provided compelling data indicating that PRGN-2012 results in significant reductions in the need for surgical procedures, suggesting a favorable acceptance among specialists in the field. Additionally, the high likelihood of approval by the August 27, 2025 PDUFA date further enhances the optimism surrounding Precigen's future revenue streams and market presence.

Bears say

Precigen Inc faces significant challenges in maintaining or growing its reported sales due to adverse dynamics in the broader volume and pricing environment as well as intra-market competition. The company has a history of financial losses and has not demonstrated consistent profitability, heightening concerns about its long-term viability. Additionally, balance sheet risks further complicate its financial outlook, raising questions about its operational stability and capacity to compete effectively.

Precigen (PGEN) has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Precigen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Precigen (PGEN) Forecast

Analysts have given Precigen (PGEN) a Buy based on their latest research and market trends.

According to 3 analysts, Precigen (PGEN) has a Buy consensus rating as of Oct 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Precigen (PGEN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.